MDXHEALTH (MDXH) Stock Price & Overview
NASDAQ:MDXH • BE0974461940
Current stock price
The current stock price of MDXH is 2.05 USD. Today MDXH is up by 1.49%. In the past month the price decreased by -38.62%. In the past year, price increased by 30.57%.
MDXH Key Statistics
- Market Cap
- 55.941M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.67
- Dividend Yield
- N/A
MDXH Stock Performance
MDXH Stock Chart
MDXH Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MDXH. When comparing the yearly performance of all stocks, MDXH is a bad performer in the overall market: 74.13% of all stocks are doing better.
MDXH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDXH. Both the profitability and financial health of MDXH have multiple concerns.
MDXH Earnings
On February 26, 2026 MDXH reported an EPS of -0.17 and a revenue of 29.55M. The company missed EPS expectations (-32.28% surprise) and missed revenue expectations (-5.13% surprise).
MDXH Forecast & Estimates
12 analysts have analysed MDXH and the average price target is 7.55 USD. This implies a price increase of 268.2% is expected in the next year compared to the current price of 2.05.
For the next year, analysts expect an EPS growth of 40.63% and a revenue growth 27.02% for MDXH
MDXH Groups
Sector & Classification
MDXH Financial Highlights
Over the last trailing twelve months MDXH reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 47.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.29% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MDXH Ownership
MDXH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.26 | 364.897B | ||
| AMGN | AMGEN INC | 15.33 | 183.284B | ||
| GILD | GILEAD SCIENCES INC | 16.01 | 172.309B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.9 | 109.705B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 80.376B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.86 | 42.375B | ||
| INSM | INSMED INC | N/A | 35.141B | ||
| NTRA | NATERA INC | N/A | 29.66B | ||
| BIIB | BIOGEN INC | 11.19 | 25.773B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.48 | 24.795B | ||
| MRNA | MODERNA INC | N/A | 19.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.082B | ||
| INCY | INCYTE CORP | 12.52 | 18.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDXH
Company Profile
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Company Info
IPO: 2006-06-26
MDXHEALTH
CAP Business Center, Rue d'Abhooz 31
Herstal LIEGE BE
Employees: 312
Phone: 3243642070
MDXHEALTH / MDXH FAQ
Can you describe the business of MDXHEALTH?
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
What is the stock price of MDXHEALTH today?
The current stock price of MDXH is 2.05 USD. The price increased by 1.49% in the last trading session.
Does MDXH stock pay dividends?
MDXH does not pay a dividend.
How is the ChartMill rating for MDXHEALTH?
MDXH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for MDXH stock?
12 analysts have analysed MDXH and the average price target is 7.55 USD. This implies a price increase of 268.2% is expected in the next year compared to the current price of 2.05.
Can you provide the sector and industry classification for MDXHEALTH?
MDXHEALTH (MDXH) operates in the Health Care sector and the Biotechnology industry.
What is MDXHEALTH worth?
MDXHEALTH (MDXH) has a market capitalization of 55.94M USD. This makes MDXH a Micro Cap stock.